Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +50

Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

📊 Amgen (AMGN) reported Q1 2026 revenue of $8.62 billion, a 5.8% increase year-over-year.

💰 Earnings per share reached $5.15, surpassing the analyst consensus estimate of $4.73 with an 8.87% surprise.

📈 Repatha generated total product sales of $876 million, exceeding estimates by 33.5% year-over-year.

⚠️ Enbrel showed a significant decline in performance with total sales of $320 million compared to a 37.3% drop from the previous year.

📉 Prolia reported total sales of $727 million, reflecting a 33.9% decrease year-over-year despite analyst estimates of $831.86 million.

💊 BLINCYTO demonstrated strong growth in ROW markets with sales of $194 million against an estimate of $118.06 million.

🇺🇸 Nplate showed positive momentum in the U.S. market with revenue of $283 million, up 40.8% from last year.

📉 XGEVA declined in the U.S. region to $228 million, which is -36.7% lower than the same period last year.

📊 Amgen's stock returned -4.3% over the past month compared to the S&P 500's gain of +12.2%.

⚖️ The company holds a Zacks Rank #3 (Hold), suggesting potential performance aligned with the broader market.

🔬 The article highlights various other drugs like Vectibix, KYPROLIS, and Nplate alongside their specific sales figures and estimates.

🌐 Amgen's total revenue beat the consensus estimate of $8.47 billion by 1.71%.

⏱️ Repatha sales in international regions (ROW) rose to $411 million, representing a 31.3% increase from last year.

💻 The article transitions into unrelated promotional content about quantum computing and other stocks like Lightspeed Commerce.

📄 The report is attributed to Zacks Investment Research, which emphasizes earnings estimate revisions as a driver for stock prices.

Bullish Signals
  • Amgen reported revenue of $8.62 billion for Q1 2026, representing a positive 5.8% increase year-over-year.
  • The company beat Wall Street expectations on both fronts, delivering a +1.71% revenue surprise and an impressive +8.87% EPS surprise.
  • Repatha sales in international regions (ROW) surged 31.3% year-over-year to $411 million, significantly exceeding the analyst consensus of $373.03 million.
  • BLINCYTO sales were a standout success story with a massive 100% year-over-year growth and total global sales of $415 million, beating estimates by seven analysts.
  • Nplate revenue grew over 31% year-over-year in both the U.S. and globally, demonstrating strong momentum in this new product segment.
  • Kymirs (Kyprolis) generated $328.67 million in sales, aligning closely with analyst estimates and showing stable demand.
Risk Factors
  • Amgen's stock returned -4.3% over the past month, significantly underperforming the Zacks S&P 500 composite which gained +12.2% during the same period.
  • Product sales for Enbrel- Total were $320 million, missing the seven-analyst average estimate of $426.94 million by approximately $107 million, representing a year-over-year decline of -37.3%.
  • Sales for XGEVA- U.S. ($228 million) fell short of the six-analyst average estimate of $238.6 million and saw revenue drop -36.7% year-over-year to $228 million versus the prior period.
  • Product sales for Prolia- Total reached $727 million, which is below the seven-analyst average estimate of $831.86 million, indicating a -33.9% year-over-year change.
  • XGEVA- Total sales ($411 million) underperformed the seven-analyst average estimate of $389.57 million and experienced a significant -27.4% decline compared to the year-ago quarter.
  • Amgen's shares are currently assigned a Zacks Rank #3 (Hold), suggesting analysts expect the stock to perform in line with the broader market rather than outperform.
Full Analysis
For the quarter ended March 2026, Amgen (AMGN) reported total revenue of $8.62 billion, marking a 5.8% increase over the same period last year. The company delivered earnings per share (EPS) of $5.15, compared to $4.90 in the year-ago quarter. Both figures surpassed Wall Street expectations, with revenue exceeding the Zacks Consensus Estimate of $8.47 billion by +1.71% and EPS beating the consensus estimate of $4.73 by +8.87%. Detailed product sales data revealed mixed performance across Amgen's key offerings. Repatha emerged as a standout performer, with total sales reaching $876 million compared to an analyst average of $819.8 million, representing a +33.5% year-over-year change. Nplate also showed strong growth with total sales of $412 million versus estimates of $339.63 million, a +31.6% increase. Conversely, Enbrel faced significant headwinds, reporting total sales of $320 million against an analyst average of $426.94 million, reflecting a -37.3% decline from the prior year. XGEVA total sales dropped by 27.4% to $411 million versus estimated figures, while Prolia sales fell 33.9% year-over-year to $727 million. Following the earnings release, Amgen shares declined -4.3% over the past month, contrasting with the Zacks S&P 500 composite's +12.2% gain. The stock currently holds a Zacks Rank #3 (Hold), suggesting expectations of performance in line with the broader market. While the article notes that radical new technology such as quantum computing is emerging, this specific section serves as an advertisement for unrelated investment reports and does not impact Amgen's financial results or current market position.